spin
Having seen how the press release sausage is made up close, I chose my words carefully. I very much doubt that those were Dr. Sidor's words, but rather the words of a PR person which were intended to convey encouragement that the next phase in the development of MKC-1 can proceed. The fact that this next phase depends of the harsh reality of median progression free survival (or progression or death in half the patients, which is the same thing) is not something about which I would expect a PR person to think, or to look beyond the euphemistic clinical trial language.
Like rubberchicken said, "efficacy endpoint" sure sounds better than a sharp stick to the eye, even though most patients would rather have the stick's endpoint in their eye than being a contributor to the efficacy endpoint statistic.
Best Regards,
C-Peptide
Market Data 
Markets 
AI
